| Title | Disease Status | Description | Eligibility | |
| Lung | ACORN II | NSCLC-Stage IIIB/IV second line | Observational Study of the Costs & Health Resource Utilization of Erlotinib & Infused Chemotherapy in NSCLC |
|
| Attract-1 (CASA404) | NSCLC-Stage IIIB/IV | ASA404 in combination with paclitaxel-carboplatin chemotherapy in the tx of patients with stage IIIB/IV NSCLC. First line tx. |
|
|
| NHL | RATE | Non-Hodgkin’s Lymphoma-Follicular B-Cell-1st line | Phase III Rituxuimab Faster Infusion Time In Patients With Previously Untreated Diffuse Large B-Cell or Follicular NHL |
|
| Head &Neck | LORHAN | Head and Neck
-Previously untreated |
Registry of patients receiving therapy other than Surgical Resection alone for Newly Diagnosed Head and Neck CA |
|
| PNH | PNH Registry | PNH Diagnoses | Registry of any patients positive f or PNH or on |
|
| GIST | reGISTry | GIST |
Gastrointestinal Stromal Tumor Registry Protocol |
|
| Colon | SPIRITT | Colon
-Second Line Treatment for mCRC |
Open labeled Randomized, Phase 2 trial of FOLFIRI with Panitumimab or Avastin as second-line TX in subjects with mCRC with wild –type KRAS tumors |
|
| Multiple Myeloma | UP FRONT | Multiple Myeloma-with related organ or tissue damage | Randomized, Phase3b Trial: VELCADE, Thalidomide & Dexamethasone (VTD) vs. VELCADE, & Dexamethasone (VD) vs. VELCADE, Melphalan & Prednisone (VMP) in previously untreated Pts who are not candidates for high dose Chemo or Autologous Stem Cell Transplant. |
|
| Breast | BEATRICE | Breast- Stage I-III, Triple Negative | International open-label 2-arm phase III trials of adjuvant Avastin in triple Negative breast cancer. |
|
| VIRGO | Breast Cancer-Metastatic or Locally Recurrent DZ | Observational Study of Treatment Patterns and Safety outcomes for Metastatic or Locally Recurrent Breast Cancer |
|